Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Enterovirus 71 inactivated vaccine (Anhui Zhifei Longkema)
- Development stage
- Unknown
- Lead developer
- Zhifei Biological
- Modality
- Whole Inactivated Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The Enterovirus 71 inactivated vaccine, developed by Anhui Zhifei Longkema Biopharmaceutical, is an inactivated virus vaccine designed to prevent hand, foot, and mouth disease (HFMD) caused by Enterovirus 71 (EV71) in susceptible persons aged 6 months and older. The vaccine works through inactivated EV71 antigens that induce protective neutralizing antibodies against Enterovirus 71, thereby preventing EV71-associated HFMD. This vaccine is one of the EV71 inactivated vaccines licensed in China, which are the world's only EV71 vaccines approved by a national regulatory authority. The biological target is Enterovirus 71, a major causative agent of HFMD that can lead to severe neurological complications in children. The modality is an inactivated virus vaccine, meaning it contains killed viral particles that stimulate an immune response without causing disease.
- Other names
- 肠道病毒71型灭活疫苗EV71 inactivated vaccineEV-71 inactivated vaccineEV 71 inactivated vaccine
Beyond the preview
Go deeper on Enterovirus 71 inactivated vaccine (Anhui Zhifei Longkema).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Enterovirus 71 inactivated vaccine (Anhui Zhifei Longkema).